|Quick Links

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM 10-QSB

(Mark One)

[ x ]     QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2001
OR

[    ]       TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE ACT

For the transition period from
 to
Commission File Number 1-11055

Epigen, Inc.(Exact name of small business issuer as specified in its charter)

Delaware(State or other jurisdiction of incorporation or organization)

04-3120172(I.R.S. Employer Identification No.)

69 North Tower Hill Road, PO Box L, Millbrook, NY 12545(Address of principal executive offices) (Zip Code)

(845) 677-5317(Issuer's telephone number, including area code)

n/a(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Exchange Act during the past 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.   YES [ x ]   NO [   ]

The number of shares outstanding of the issuers Common Stock, par value $.001 per share, at
August 13, 2001 was 13,929,450.

Transitional Small Business Disclosure Format (check one):  
YES [ x ]   NO [   ]
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|EPIGEN, INC.
                         (Formerly COD Associates, L.P.)
                          (A Development Stage Company)

                                     INDEX


                                                                           Page
                                                                          Number
                                                                          ------
PART I    FINANCIAL INFORMATION

Item 1.   Financial Statements
          Balance Sheets
             at June 30, 2001 and December 31, 2000.....................      1

          Statements of Operations
             for the six month periods ended June 30, 2001
             and June 30, 2000, and for the three month periods
             ended June 30, 2001 and June 30, 2000, and cumulative
             from inception (January 28, 1987) to June 30, 2001.........      2

          Statements of Cash Flows
             for the six month periods ended June 30, 2001
             and June 30, 2000, and cumulative from
             inception (January 28, 1987) to June 30, 2001..............      3

          Notes to Financial Statements.................................  4 - 6

Item 2.   Management's Discussion and Analysis or Plan of Operation.....  7 - 9

PART II   OTHER INFORMATION

Item 2(c) Information Regarding the Sale of Unregistered Securities
          During the Three Month Period Ended June 30, 2001.............     10

Item 6.   Exhibits and Reports on Form 8-K..............................     10


SIGNATURES..............................................................     11
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|PART I     FINANCIAL INFORMATION

Item 1.  Financial Statements

EPIGEN, INC.
                              (Formerly COD Associates, L.P.)
                               (A Development Stage Company)
                                      BALANCE SHEETS


                                                                 June 30,      December 31,
                                                                   2001            2000
                                                              -------------   -------------
ASSETS
Current Assets:
   Cash and cash equivalents ..............................   $    160,259    $     59,199
   Loan and interest receivable ...........................        105,532         164,165
                                                              -------------   -------------
      Total Current Assets ................................        265,791         223,364

Office equipment, net of accumulated depreciation of
   $57,411 and $55,276 ....................................         12,727          14,862
                                                              -------------   -------------
      Total Assets ........................................   $    278,518    $    238,226
                                                              =============   =============

LIABILITIES & STOCKHOLDERS' EQUITY
Current Liabilities:
   Note payable demand ....................................   $    105,805    $    105,805
   Notes payable - Officer ................................        304,142         361,214
   Accrued interest - notes payable .......................        102,733          97,019
   Accrued direct research & development costs ............        643,014         570,252
   Accrued professional fees ..............................        374,892         359,858
   Accrued payroll ........................................        366,706         291,182
   Other accrued expenses .................................        106,989         199,997
                                                              -------------   -------------
      Total Current Liabilities ...........................      2,004,281       1,985,327
                                                              -------------   -------------

STOCKHOLDERS' EQUITY
   Preferred Stock - 15,000,000 shares authorized of which:
     3,000,000 shares designated as Series A, $.001 par
       value, issued and outstanding - 1,843,306 shares at
       June 30, 2001 ......................................          1,843           1,843
     500,000 shares designated as Series B, $.001 par
       value, issued and outstanding - 375,000 shares at
       June 30, 2001 ......................................            375             375
   Common Stock - 50,000,000 shares authorized,
     $.001 par value, issued and outstanding - 13,905,450
       shares at June 30, 2001 ............................         13,905          12,567
   Additional paid-in capital .............................     20,965,484      19,999,152
   Deficit accumulated during development stage ...........    (22,707,370)    (21,761,038)
                                                              -------------   -------------
      Total Stockholders' Equity ..........................     (1,725,763)     (1,747,101)
                                                              -------------   -------------

      Total Liabilities & Stockholders' Equity ............   $    278,518    $    238,226
                                                              =============   =============

        The accompanying notes are an integral part of these financial statements.

                                            -1-
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|EPIGEN, INC.
                                                   (Formerly COD Associates, L.P.)
                                                    (A Development Stage Company)
                                                      STATEMENTS OF OPERATIONS

                                                                                                                       Cumulative
                                                       For the Three   For the Three   For the Six     For the Six        from
                                                       Months Ended    Months Ended    Months Ended    Months Ended    Inception to
                                                         June 30,        June 30,        June 30,        June 30,        June 30,
                                                           2001            2000            2001            2000            2001
                                                       -------------   -------------   -------------   -------------   -------------
Revenues:
 Contract research .................................   $       --      $       --      $       --      $       --      $      5,000
 Licensing fees ....................................           --              --              --              --             1,600
 Management fee income .............................           --              --              --              --            23,219
 Interest income ...................................          3,120          25,630           6,587          25,630         258,996
                                                       -------------   -------------   -------------   -------------   -------------
                                                              3,120          25,630           6,587          25,630         288,815
                                                       -------------   -------------   -------------   -------------   -------------
Operating Costs & Expenses:
 Direct research & development .....................        194,174         194,880         290,256         336,433       9,060,594
 General & administrative ..........................        315,072         279,903         636,524         497,174      11,980,831
 Fees due to General Partner of the Predecessor
  & affiliates, forgiven and contributed to capital            --              --              --              --         1,188,893
 Interest expense, net .............................         13,129          31,877          26,140         106,483         974,462
                                                       -------------   -------------   -------------   -------------   -------------
      Total Operating Costs & Expenses .............        522,375         506,660         952,920         940,090      23,204,780
                                                       -------------   -------------   -------------   -------------   -------------

Net (loss) before extraordinary items ..............       (519,255)       (481,030)       (946,333)       (914,460)    (22,915,965)

Extraordinary Item:
 Cancellation of debt income .......................           --              --              --              --           208,594
                                                       -------------   -------------   -------------   -------------   -------------

Net (loss) .........................................   $   (519,255)   $   (481,030)   $   (946,333)   $   (914,460)   $(22,707,371)
                                                       =============   =============   =============   =============   =============

Net (loss) per common share ........................   $      (0.04)   $      (0.08)   $      (0.07)   $      (0.16)
                                                       =============   =============   =============   =============

Weighted average number
 of shares of Common Stock outstanding .............     13,647,343       5,848,170      13,457,326       5,832,187
                                                       =============   =============   =============   =============

                             The accompanying notes are an integral part of these financial statements.

                                                                 -2-
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|EPIGEN, INC.
                                     (Formerly COD Associates, L.P.)
                                      (A Development Stage Company)
                                        STATEMENTS OF CASH FLOWS

                                                                                            Cumulative
                                                           For the Six     For the Six         from
                                                           Months Ended    Months Ended    Inception to
                                                             June 30,        June 30,        June 30,
                                                               2001            2000            2001
                                                           -------------   -------------   -------------
Cash Flows From Operating Activities:
 Net loss ..............................................   $   (946,333)   $   (914,460)   $(22,707,371)
 Adjustments to reconcile net loss to
  net cash used in operating activities:
   Depreciation and amortization expense ...............          2,135           3,002         118,356
   Non-cash expenses paid in equity interest ...........           --                 4       2,811,376
   Non-cash compensation expense associated
    with the grant of stock options and warrants .......           --              --           427,964
 Debt converted to equity ..............................         45,620       1,387,165       3,878,757
 Changes in operating assets and liabilities:
  Increase (decrease) in accrued direct
   research and development costs ......................         72,762         (13,940)        643,014
  Increase (decrease) in accrued professional fees .....         15,034         (15,248)        374,892
  Increase (decrease) in accrued payroll ...............         75,524      (1,192,940)        366,706
  Increase (decrease) in accrued expenses to
   affiliates, printing charges and other expenses .....        (87,294)      1,400,708         209,722
                                                           -------------   -------------   -------------
     Net Cash Provided By (Used In) Operating Activities       (822,552)        654,291     (13,876,584)
                                                           -------------   -------------   -------------

Cash Flows From Investing Activities:
 Purchase of office equipment ..........................           --              --           (74,133)
 Retirement of treasury stock ..........................           --               347            --
 Decrease (increase) in note payable from an officer/
  shareholder ..........................................        (57,072)       (157,097)        (57,072)
 Decrease (increase) in note and interest receivable
  from an officer/shareholder ..........................         58,633            --          (105,532)
 Decrease (increase) in other assets ...................           --              --            (3,025)
 Increase in organizational costs ......................           --              --           (53,925)
                                                           -------------   -------------   -------------
     Net Cash Provided By (Used In) Investing Activities          1,561        (156,750)       (293,687)
                                                           -------------   -------------   -------------

Cash Flows from Financing Activities:
 Proceeds from issuance of Common Stock ................        922,051            --        10,901,911
 Increase (decrease) in note payable - Officer .........           --              --           361,214
 Capital contributions .................................           --              --         2,141,600
 Proceeds from issuance of Preferred Stock .............           --           225,000         820,000
 Increase (decrease) in note payable-demand ............           --           (15,000)        105,805
 Net decrease in notes payable - other .................           --        (1,125,000)           --
                                                           -------------   -------------   -------------
     Net Cash Provided By (Used In) Financing Activities        922,051        (915,000)     14,330,530
                                                           -------------   -------------   -------------

Net increase (decrease) in cash and cash equivalents ...        101,060        (417,459)        160,259
Cash and cash equivalents, beginning period ............         59,199         521,766            --
                                                           -------------   -------------   -------------

Cash and cash equivalents, end of period ...............   $    160,259    $    104,307    $    160,259
                                                           =============   =============   =============

               The accompanying notes are an integral part of these financial statements.

                                                   -3-
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS1.  Basis of Presentation

The financial statements as
of June 30, 2001 are unaudited, but include all adjustments (consisting of
normal, recurring adjustments) which the Company considers necessary for a fair
presentation of such interim financial statements. The results of operations for
the six month periods ended June 30, 2001 and June 30, 2000, and the three month
periods ended June 30, 2001 and June 30, 2000 are not necessarily indicative of
the results for the entire year. The financial statements and notes are
presented as permitted by Form 10-QSB and do not contain certain information
included in the Companys annual financial statements and notes.

2. Cash and Cash Equivalents

Cash and cash equivalents
include all funds held in checking and money market bank accounts.

3.  Net Loss per Share

Net loss per share is based
on the weighted average number of shares of Common Stock outstanding during the
period. All outstanding warrants and options have been excluded from the
calculation as they are antidilutive.

4.  Licensing Agreements

The Companys
technology was originally licensed from Boston Biomedical Research Institute
(BBRI). In 1993, BBRI transferred ownership of all licensed
technology to Epigen, Inc. Conditions in the transfer of ownership provide,
among other things, for royalty payments to BBRI. Currently, royalty payments to
BBRI are capped at 3% of the net selling price of products containing Human
Carcinoma Antigen or epiglycanin.

During 1992, the Company
entered into a contract with the University of Oslo (Oslo
University) in close collaboration with BBRI for the characterization of
the Human Carcinoma Antigen. The agreement calls for payment to Oslo University
of 1% of net sales for any human therapeutic product utilizing these patent or
biological material rights sold to third parties.

During 1993, the Company
entered into an agreement with Massachusetts General Hospital (MGH)
to license certain antibodies for use in developing the in-vitro diagnostic
test, the in-vivo imaging agent and the therapeutic vaccine. Under the
agreement, the Company is required to pay royalties ranging from 2% to 5% of the
net sales price, as defined, depending on the country in which the product is
sold. The term of the agreement expires, on a country-by-country basis, eight
years after the first commercial sale or for the life of a valid patent in a
country, whichever occurs first.
-4-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS4.  Licensing Agreements (continued)

Pursuant to the
Companys agreement with BBRI, if royalties are to be paid to both BBRI and
MGH, the aggregate royalty payable to BBRI and MGH shall not exceed 6% of the
net proceeds to the Company from sales of any licensed product or process. On
June 12, 1995, MGH agreed to reduce royalty payments due pursuant to the June 1,
1993 agreement by 50% to between 1% and 2.5%.

The Company entered into an
agreement dated as of March 31, 1999 with Vacold, LLC for the creation of an IgG
antibody. In lieu of cash, Vacold received 433,705 shares of the Companys
Common Stock. In addition, Vacold is to receive a 3% royalty on Epigens
sales that include any IgG antibodies developed in Vacolds laboratory. A
second contract was negotiated with Vacold for ongoing R&D. Vacold was to be
responsible for the optimization and demonstration of the new assay to
prospective strategic partners. The Agreements with Vacold were terminated on
September 28, 2000 by mutual consent.

The Company has opened a
new laboratory at the University of Rochester (the University) in
Rochester, New York to continue the development of its diagnostics for the
period February 1, 2001 to January 31, 2002. Under the terms of the License
Agreement, the rent to be paid to the University will be $3,333.00 per month. In
conjunction with this Agreement, there is a Restricted Stock Agreement with the
Research Foundation of the University of Rochester (the Foundation)
for the period February 1, 2001 to January 31, 2002 whereby the Foundation is to
receive 26,087 shares of Common Stock of the Company. The shares of stock shall
accrue to the Foundation one twelfth of the stipulated amount on a monthly
basis. For the month of April 2001, the Foundation received 2,174 shares of
Common Stock. 4,348 shares have accrued, covering the period May 1, 2001 to June
30, 2001.

5.  Loan and Interest Receivable

On June 7, 2000, Donald C.
Fresne, Chairman of the Board and Chief Executive Officer of the Company, issued
a Promissory Note to Epigen, Inc. in the amount of $156,214 at an annual
interest rate of 9%. The terms of the Note state that three annual equal amounts
of the principal together with interest accrued on the outstanding amount shall
be paid in coordination with a note payable to Donald C. Fresne, (see Note 6)
commencing on June 1, 2001. The total obligation on June 1, was $66,609.65.

6.  Loan and Interest Payable

Included in Notes payable -
Officer, is a Promissory Note dated June 7, 2000 issued by Epigen, Inc. to
Donald C. Fresne, Chairman of the Board and Chief Executive Officer of the
Company, in the amount of $356,214 at an annual interest rate of 9%. The terms
of
-5-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS6.  Loan and Interest Payable (continued)

the Note state that
$156,214 of this amount shall be paid back together with interest thereon in
three equal annual installments commencing on June 1, 2001. The total obligation
was $66,609.65. This was coordinated with a loan and interest receivable from
Donald Fresne (see Note 5).

7.  Equity Transactions During the Three Months Ended June 30, 2001

A consultant to the Company
converted $22,620 of fees owed in exchange for 19,652 shares of Common Stock.
These shares were recorded at par value, with the balance of the price recorded
as additional paid in capital.

The Companys attorney
indirectly purchased 17,000 shares of Common Stock for $19,550. These shares
were recorded at par value, with the balance of the price recorded as additional
paid in capital.

The Company issued an
additional 6,522 shares of Common Stock in coordination with a licensing
agreement as enumerated in Note 4. The value of these shares for purposes of the
licensing agreement is $1.15 per share totaling $7,500. The shares were issued
at par with the balance of the price recorded as additional paid in capital.

A shareholder of the
Company agreed to exercise his Series I Warrants to acquire an additional
975,000 shares of the Companys Common Stock for an agreed upon price of
$550,000. The shares were issued at par value with the balance of the price
recorded as additional paid in capital.
-6-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)

Item 2.  Management's Discussion and Analysis or Plan of Operation

The Company presently is
insolvent and unable to pay its debts as they become due. Certain of the
officers have agreed temporarily to allow part of their salaries to accrue.
Currently, liabilities exceed assets. Should a sufficient number of the
Companys creditors pursue the obligations owed them, the Company might be
forced into a voluntary or involuntary bankruptcy.

During the period from June
28, 2000 through August 2, 2000, however, the Company completed a series of
conversions of debt to stock, primarily with existing stockholders and the
Companys officers, which reduced its outstanding liabilities by an
aggregate of $2,966,415 from $4,607,906 to $1,641,491. As a result of such
conversions, the Company issued an aggregate of 2,393,114 shares of its Common
Stock, and 1,493,306 shares of its Series A Preferred Stock. The Company is
continuing its efforts to reduce its liabilities through equity conversions as
appropriate opportunities are presented.

In addition to debt
reduction, the Company continues to pursue funding from a variety of sources.
Effective July 12, 2001, the Company entered into a letter of intent for the
private placement of up to $7,000,000 of the Companys securities. However,
there can be no assurance that such private placement will be successful or that
the Company will be successful in its efforts otherwise to raise additional
capital.

The Company believes that
it has produced enough data indicating that the HCA Test can be used as a
confirmatory test for prostate cancer. The Company is currently negotiating a
license agreement for the distribution of the HCA Test with a major
biopharmaceutical firm.

The Company does not
presently have the resources to complete the development of, or conduct
prospective clinical trials on, new products. It has never been part of the
Companys strategy to market any of its products. The Company is focusing
on the optimum financial opportunity this technology should afford, and is
presently negotiating a license agreement with a major biopharmaceutical company
to distribute our product upon FDA approval. The terms and conditions of such
agreement are acceptable to the Company. No assurance can be made that the
Company will be successful in negotiating a definitive license agreement or
that, upon execution, the Company will be able to complete development of the
HCA Test in order to receive FDA approval or to commence its manufacture and
distribution.

Upon funding, the Company
intends to complete the development of and conduct prospective clinical trials
on its confirmatory test for prostate cancer, a prerequisite for seeking FDA
approval. The Company is currently planning to manufacture the test in its own
facilities, and will furnish its distributors with a finished product.

The Company has hired Paul Schnipelsky, Ph.D., former Vice President of Research from Ortho-Clinical Diagnostics,
John L. Daiss, Ph.D., former Fellow, John C. Mauck, Ph.D., and several technicians formerly employed by
Ortho-Clinical Diagnostics, Inc.  The Company opened a laboratory at the University of Rochester in Rochester,
New York to continue the development of its products.

-7-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
Item 2.  Management's Discussion and Analysis or Plan of Operation (continued)

The Company continues to
pursue its business plan to the extent resources permit.

The Company, through
collaborations with hospitals in the Northeast and a major biopharmaceutical
company, has completed a large clinical study on over 400 prostate cancer
patients. The Company believes that the results demonstrate the viability of the
HCA Test as a diagnostic aid. The study reveals the following results in a
comparison between its HCA and PSA:
Parameter       HCA            PSA
            -----------     -----     -----------------
            Sensitivity     96.4%     (94%, 99%)  81.5%
            Specificity     92.2%     (89%, 96%)  51.6%
            PPV(1)          90.9%     (87%, 95%)  57.5%
            NPV(2)          97%       (95%, 99%)  77.6%

     (1) Positive Predictive Value
     (2) Negative Predictive Value
The above table was
developed in collaboration with a major biopharmaceutical company.

Sensitivity is a measure of
true positive or false negative. If there are 100 lesions and a test identifies
80 of these, the sensitivity is 80%. True (+) 80, false negative (20).

Specificity is a measure of
true negative or false positive. If there are 100 patients with no lesions and a
test identifies 20 lesions, the specificity is 80%. True (-) 80, false (+) 20.

The study was conducted
using IgM antibodies. The industry prefers IgG antibodies because of their
smaller size and faster reactivity. The Company has successfully raised IgG
antibodies that are 20% of the size of IgM antibodies. These antibodies have
faster reactivity and avoid problems indigenous to IgM antibodies. The Company
is now optimizing its assay, or testing the various combinations of IgG
antibodies to determine which combination gives the best results.

The Company has also
entered into other collaborations with hospitals to develop a confirmatory test
for breast cancer. One of the collaborators has collected serum samples from 500
patients who have had positive mammograms and subsequent biopsies. This will
allow the Company to demonstrate the ability of the HCA Test to differentiate
between cancer and normals, and confirm the presence of a carcinoma. It is
generally accepted that mammograms have a 95% false positive rate. The Company
believes that the HCA Test should drop this false positive rate to 5 - 10%. The
Company believes from in-house preliminary data that the HCA Test should also be
an effective confirmatory test for breast cancer. As soon as these data are
available, a presentation will be made to prospective strategic partners with
the intent to license the technology. If successful, the Company believes that
the HCA Test will eliminate the need for unnecessary sonograms and biopsies,
reduce stress experienced by patients who have false positives, and result in
substantial savings to the health care industry.

-8-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)
Item 2.  Management's Discussion and Analysis or Plan of Operation (continued)

In October 2000, the
Company entered into a Memorandum of Understanding (MOU) with
Medarex, Inc., a biopharmaceutical company, to jointly develop and market the
Companys monoclonal antibody therapeutic utilizing the Companys
patented antigen. The definitive agreement is currently being negotiated.

Preliminary in-vitro
testing regarding the Companys therapeutic has shown that the vaccine
kills cancer cells within an hour without harm to normal cells. Research on the
Companys vaccine at Columbia Presbyterian has been deferred until funding
is available. When the definitive collaboration agreement with Medarex, Inc. is
completed, the Company and Medarex, Inc. will initiate various procedures
designed to lead to the development of human antibodies for use in a monoclonal
antibody therapeutic.

On June 6, 2001, the
Company signed an MOU with AltaRex Corp. The MOU creates a joint collaboration
with AltaRex to develop a therapeutic for epithelial cancers that will
incorporate Epigens monoclonal antibodies and the HCA antigen in
Altarexs unique and proprietary immunization strategy. Altarexs
technology combines the elevated levels of tumor-associated antigens frequently
observed in the blood of cancer patients with low levels of non-human antibodies
to form highly immunogenic circulating immune complexes that can induce the
patients own potent immune response against the tumor. Specifically,
combinations of Epigens anti-HCA antibodies and HCA will be evaluated for
immunogenic potential in Altarexs Dendritic Cell Assay System. Potent
immunogenic combinations will be selected for further investigation and rapid
development for Phase I clinical trials.

-9-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)

PART II     OTHER INFORMATION

Item 2(c)  Information Regarding the Sale of Unregistered
Securities During the Three Month Period Ended June 30, 2001

In April 2001, Registrant
issued to Lionel Goldfrank III 600,000 shares of its Common Stock at a price of
$.54 per share. Registrant also issued 19,652 shares of its Common Stock to a
service provider in lieu of cash for such services. Registrant valued such
shares at $1.15 per share.

In May 2001, Registrant
issued to an affiliate of the University of Rochester 6,522 shares of the
Registrants Common Stock in lieu of a portion of the rent owed by
Registrant to the University of Rochester for the lease of laboratory space. The
issuance of such shares in lieu of cash is required pursuant to
Registrants lease for such space. In addition, Registrant issued 17,000
shares of its Common Stock to its general counsel. All of such shares were valued by
Registrant at $1.15 per share.

In June 2001, Registrant
issued 375,000 shares of its Common Stock to Lionel Goldfrank III upon his
exercise of Series I Warrants to purchase such shares. Mr. Goldfrank agreed to
exercise such Warrants to assist Registrant with its cash flow needs. In
consideration for such exercise, Registrant agreed to reduce the exercise price
for the Warrants exercised to $.60 per share.

Registrant relied on
Section 4(2) of the Securities Act of 1933, as amended, in issuing all such
securities in light of the fact that such securities were issued on a limited
basis, without publication, and the recipients of such securities are familiar
with Registrant and its operations.

Item 6.      Exhibits and Reports on Form 8-K

(a) Exhibits-None(b) Reports on Form 8-KThe Company did not file any reports on Form 8-K during the three month period ended June 30, 2001.-10-
EPIGEN, INC.
(Formerly COD Associates, L.P.)
(A Development Stage Company)SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.

Dated:  August 13, 2001
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | EPIGEN, INC.
| |  | ------------
| |  | By:         

| |  | EPIGEN, INC.
| |  | ------------
| |  | By:         

|-11-
Quick Links
PART IFINANCIAL INFORMATION

   Item 1.  Financial Statements

        Balance Sheets
        Statements of Operations
        Statements of Cash Flows
        Notes to Financial Statements

   Item 2.  Management's Discussion and Analysis of Financial Condition and Results of OperationsPART IIOTHER INFORMATION
   Item 2(c) Information Regarding the Sale of Unregistered Securities During the Three Month Period Ended June 30, 2001
   Item 6.  Exhibits and Reports on Form 8-K
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------